AMS

Chipmaker AMS reported a more than tenfold increase in fourth-quarter profit as the Austria-based group benefited from rising demand for the sensors it makes for smartphone producers such as Apple.

ROCHE

* Phase III Immotion151 study showed Genentech’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer

Bristol-Myers Squibb Co provided some positive data on its immuno-oncology drugs for the most lucrative lung cancer market but it fell short of giving clarity on its ability to compete with a rival treatment from Merck & Co Inc.

COMPANY STATEMENTS

* Idorsia reported liquidity of 1.09 billion Swiss francs and the end of 2017 and said it expected non-GAAP operating expenses of around 390 million this year

* Lalique Group says partnership with Damian Ltd, announced in November and supposed to be completed in January 2018, has been delayed by technical issues and is now expected to take place in the second quarter of 2018. “Both parties remain fully committed to the transaction,” it says.